...
首页> 外文期刊>Clinical lymphoma, myeloma & leukemia >Complete response to thalidomide and dexamethasone in a patient with necrobiotic xanthogranuloma associated with monoclonal gammopathy: a case report and review of the literature.
【24h】

Complete response to thalidomide and dexamethasone in a patient with necrobiotic xanthogranuloma associated with monoclonal gammopathy: a case report and review of the literature.

机译:坏死性黄体肉芽肿伴单克隆性丙种球蛋白病患者对沙利度胺和地塞米松的完全反应:一例病例并文献复习。

获取原文
获取原文并翻译 | 示例
           

摘要

Necrobiotic xanthogranuloma (NXG) was first described in 1980 by Kossard and Winkelmann in an article in which they discussed 8 patients with xanthomatous plaques who were noted to have monoclonal gammopathy, predominantly of the Ig(immunoglobulin)G-kappa type.(1) Since then more than 50 patients with this disorder have been described, with approximately 80% of them having an associated monoclonal gammopathy. We describe the first case, to our knowledge, of NXG with associated monoclonal gammopathy treated with thalidomide plus dexamethasone, achieving complete resolution of the skin lesions and sustaining response more than 3 years after treatment.
机译:坏死性黄体肉芽肿(NXG)于1980年由Kossard和Winkelmann在一篇文章中首次描述,他们讨论了8例黄斑性斑块的患者,这些患者患有单克隆性乳腺病,主要是Ig(免疫球蛋白)G-κ型。(1)则已有50多名患有这种疾病的患者被描述,其中大约80%患有相关的单克隆丙种球蛋白病。据我们所知,我们描述了第一个病例,即使用沙利度胺加地塞米松治疗的伴有相关性单克隆丙种球蛋白病的NXG,可完全治愈皮肤病变,并在治疗后维持3年以上的反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号